DNTH - Dianthus Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$111.91
DETAILS
HIGH:
$145.00
LOW:
$55.00
MEDIAN:
$120.00
CONSENSUS:
$111.91
UPSIDE:
29.41%
About Dianthus Therapeutics, Inc. (https://dianthustx.com)
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Marino Garcia | President, Chief Executive Officer & Director | 1966 | $1,163,750 USD |
| Simrat Randhawa | Executive Vice President and Head of R&D | 1970 | $932,680 USD |
| Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | 1989 | $786,096 USD |
| Adam Veness | Senior Vice President, General Counsel & Secretary | 1986 | – |
| Debra Segal | Head of Regulatory Affairs | – | – |
| Edward G. Carr | Senior VP & Chief Accounting Officer | 1969 | – |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. | – | – |
| Judson Taylor | Senior Vice President & Head of Technical Operations | – | – |
| Kristina Maximenko | Chief People Officer | – | – |
| Polly Hanff | Head of Quality | – | – |
| Rashieda Gluck | Head of Clinical Development Operations | – | – |
| Scott Nogi | Head of Business Operations | – | – |